Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

the results of the first secondary endpoint, the statistical plan did not provide for a formal analysis of subsequent secondary endpoints(1).

Clinically meaningful differences were observed in time to SEGA progression. Of those patients receiving everolimus, 0% of patients (0 of 78) experienced disease progression (defined as increase in SEGA volume, worsening of non-target SEGAs, appearance of new lesions or new hydrocephalus), while 15% of patients (6 of 39) on placebo progressed(1).

Clinically meaningful differences were also observed in skin lesion response rate. A partial clinical response in skin lesions (corresponding to a 50% or greater improvement) was observed by Physician Global Assessment in 42% of patients (30 of 72) receiving everolimus, compared with 11% of patients (4 of 38) receiving placebo.  No complete responses were observed(1).

Additionally, a subset of patients (n=44) in this trial had angiomyolipomas, non-cancerous kidney tumors associated with TSC(1,6). As an exploratory endpoint, an angiomyolipoma response (corresponding to a volume reduction of 50% or greater) was observed in 53% of patients (16 of 30) receiving everolimus compared to 0% of patients (0 of 14) on placebo(1).

No adverse event (AE) leading to study drug discontinuation was observed during the study. The most common AEs in the everolimus versus the placebo arm (with an incidence of at least 20% in the everolimus arm) included mouth ulceration (32% vs. 5%), stomatitis (31% vs. 21%), convulsion (23% vs. 26%) and fever (22% vs. 15%). The most common Grade 3 AEs in the everolimus versus placebo arm (with an incidence of at least 5%) were stomatitis (8% vs. 3%), fever (6% vs. 0%) and convulsion (5% vs. 5%). One Grade 4 event of gastroenteritis was reported in the everolimus arm. Adverse events were mostly mild in severity (Grade 1/2) and were largely consistent with the known safety profile of everolimus. The most clinically notable AEs were infe
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 19, 2014 Große ... Das Problem dabei ist, dass große Pharmafirmen ... Kompetenz zu teilen. Es war deshalb ... wir uns umso mehr, dass es uns gelungen ... bei Kühlketten aufzuschreiben - mit einem Vorbehalt - ...
(Date:10/17/2014)... HILL, N.C. , Oct. 17, 2014 /PRNewswire/ ... insights is a critical success factor in today,s ... must develop market research organizations that effectively and ... location, specialty or service area. ... create value and earn recognition from internal clients ...
(Date:10/17/2014)... Oct. 17, 2014 UBM Medica US announces that ... online community and information resource for neurologists and other healthcare ... Alzheimer disease , with discussions of the latest developments ... million Americans have Parkinson disease , more than the total ... Lou Gehrig disease. Diagnosis can be difficult because there ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... March 19, 2012  BioStorage Technologies, a global provider ... cold chain logistics for the bioscience industry, announced ... webinar titled, "Comprehensive Sample Management: Leveraging an Onsite ... Thursday, March 22, from 11:00 AM to 12:30 ...
... Reportlinker.com announces that a new market research ... Branded Prescription Pharmaceutical Sales ... http://www.reportlinker.com/p0799256/Branded-Prescription-Pharmaceutical-Sales-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... achieved sales of $558bn having experienced a ...
Cached Medicine Technology:BioStorage Technologies to Host Live Webinar on Optimizing the Value of Sample Assets 2Branded Prescription Pharmaceutical Sales Outlook to 2016 2Branded Prescription Pharmaceutical Sales Outlook to 2016 3Branded Prescription Pharmaceutical Sales Outlook to 2016 4Branded Prescription Pharmaceutical Sales Outlook to 2016 5
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today announced ... module enables easy administration and routing of follow-up items ... This application allows users such as Therapists to assign ... item to a specific client, categorize tasks the way ... for follow-ups. It's designed to enable easy access ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
(Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its ... GoDaddy and HostMonster are the best VPS hosting ... Server) is the method of partitioning a physical ... has the appearance and capabilities of running on ... site pays close attention to VPS products and ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
... ... ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. ... the 2009 American Society of Hematology ("ASH") Annual Meeting updated results ... pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive ...
... of Chicago have discovered a technique that is able to ... habitual snoring by screening their urine. "These findings ... test that could detect OSA in snoring children. This would ... children who snore, only about 20 to 30 percent of ...
... , OAK BROOK, Ill., Dec. 7 ... center (AMC) members for their achievements in UHC,s Supply ... are noted for modeling best practices in supply chain ... , The winners were determined using 2008 data and ...
... , , Consumers ... SILVER SPRING, Md., Dec. 6 The U.S. Food and Drug ... San Antonio Bay on or after Nov. 16 due to reports ... from this area, which is located on the Gulf of Texas. ...
... have discovered that the loss of a key segment of DNA ... to show that this kind of genetic alteration can cause obesity. ... study, led by Dr Sadaf Farooqi from the University of Cambridge ... at 300 children with severe obesity. The team scanned each ...
... find signs of feline DNA in virus , SUNDAY, Dec. 6 ... might be found in a tiger that lived thousands or millions ... virus took on a bit of a tiger,s genetic material, scientists ... to this day. That tiger, in fact, may have bitten a ...
Cached Medicine News:Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Urine test for pediatric obstructive sleep apnea possible 2Health News:Recognized Top Performers in UHC Supply Chain 2Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2
... RAM Scientifics SAFE-T-FILL Capillary Blood Collection Tubes ... Available for a wide range of applications, ... a capillary tube, attached cap and a ... to draw the blood into the micro ...
... Collection Tubes are 100% plastic capillary blood ... of applications, the Capillary Collection Tubes are ... and a micro tube.,The capillary tube uses ... the micro tube thereby eliminating the tendency ...
... The Clinical Diagnostic Solutions Medonic ... series is designed for fast, reliable ... ease. On board features include; open ... coding to ensure positive patient identification ...
... test is an enzyme immunoassay test in a ... a 90-minute incubation. The results are objective ... results. The Bio-Rad Measles IgG test is ... human IgG antibodies to measles virus in human ...
Medicine Products: